Drug Profile
HBV specific TCR redirected T-cell therapy - Lion TCR
Alternative Names: HBV antigen specific TCR redirected T cell; LioCyx; LioCyx-M; LioCyx-M004; LT-C21; mRNA HBV/TCR T-cells; T-cell receptor directed T-cell therapy; TCR-TLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Lion TCR
- Class Antineoplastics; Antivirals; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Hepatitis B
- No development reported Liver cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Liver-cancer in China (Infusion)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Liver-cancer in Singapore (Infusion)
- 01 Jun 2023 Phase-I clinical trials in Hepatitis B (In adults) in China (IV) (NCT05905731)